SonoThera raised $125 million in an oversubscribed Series B to advance ultrasound-mediated genetic medicines, using its RIPPLE delivery and PORE payload engineering platform, per the provided financing summary. The company plans to push lead programs in Duchenne muscular dystrophy (DMD) and autosomal dominant polycystic kidney disease (ADPKD) and expand targeted redosable genetic therapies across organs. The round was led by Vida Ventures and included investors such as ARK Invest, Otsuka, UCB Ventures, Illumina Ventures, and Johnson & Johnson Innovation–JJDC. SonoThera said it expects to initiate its first clinical trial in DMD in 2027. The funding underscores continued investor interest in delivery-technology differentiation—particularly approaches aiming to enable repeat dosing while mitigating delivery payload constraints and immune responses.